GLP1R and Obesity: With regard to the risk factors associated with severe COVID-19 cases, it is remarkable to note that GLP-1 receptor agonists (e.g., exendin-4, liraglutide, semaglutide) are either FDA-approved (diabetes) (115) or proposed (obesity, age-related decline) (116, 117) as an intervention for the underlying conditions.